Prescription rules for obesity drugs may unfairly exclude non-whites
The relationship between body-mass index and weight-related ailments varies by race
Potent new anti-obesity drugs can reduce body weight by 15-20%. However, regulation and costs limit who can take them. In America, the Food and Drug Administration (fda) has approved just one of the new drugs, Wegovy, for weight loss—and only for patients with a body-mass index (bmi) above certain thresholds. The cut-off is 27 for people with weight-related illnesses, and 30 otherwise. For someone 1.7 metres (5’7”) tall, these correspond to 78kg (172lb) and 87kg. People with lower bmis can try to get a prescription anyway. However, insurers rarely cover such “off-label” use of the $1,000-per-month drugs.
This article appeared in the Graphic detail section of the print edition under the headline “One size does not fit all”
More from Graphic detail
How covid contributed to a crisis of trust in America
Eight charts show how people’s confidence in the government and science has changed
Which parts of the world are becoming more prone to wildfires?
Two maps explain why fire seasons are lasting longer and becoming more dangerous
A short history of Syria, in maps
The most influential people, groups and events that shaped Syria’s role in the Middle East
Is Javier Milei’s economic gamble working?
Inflation has plunged in Argentina, but some vital goods have soared in price
How to make sense of 2024’s wild temperatures
Our climate team highlight four charts and two maps
What New York’s congestion charge could teach the rest of America
Lighter traffic in some parts of the city is a promising start. Will it continue?